2019;21: 33 40. 3. Vora AN, Dai D, Matsuoka R, et al. Incidence, management, and associ- ated clinical outcomes of new-onset atrial fibrillation following transcath- eter aortic valve replacement: an analysis from the STS/ACC TVT registry. JACC Cardiovasc Interv. 2018;11:1746 56. 4. Seeger J, Gonska B, Rodewald C, et al. Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement. JACC Cardiovasc Interv. 2017;10:66 74. 5. Jochheim D, Barbanti M, Capretti G, et al. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12:1566 76. 6. Mangner N, Crusius L, Haussig S, et al. Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implanta- tion and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation. Am J Cardiol. 2019;123:1134 41. 7. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran ver- sus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206 14. 8. De Caterina R, Renda G, Carnicelli AP, et al. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Car- diol. 2017;69:1372 82. 9. Carnicelli AP, De Caterina R, Halperin JL, et al. Edoxaban for the preven- tion of thromboembolism in patients with atrial fibrillation and biopros- thetic valves. Circulation. 2017;135:1273 5. 10. Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with war- farin in patients with atrial fibrillation and valvular heart disease: find- ings from the Apixaban for Reduction in Stroke and Other Thromboem- bolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2015;132: 624 32. 11. Guimar es PO, Pokorney SD, Lopes RD, et al. Efficacy and safety of apixa- ban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol. 